Insulet Corp

PODD

Equity

ISIN null / Valor 2941247

NASDAQ (2025-11-21)

USD 331.17+5.84%

Insulet Corp
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Insulet Corp, traded under the ticker PODD on the NASDAQ, is a prominent medical device company with its headquarters in Acton, Massachusetts. The company has established a significant global presence, with offices and manufacturing facilities spread across various locations worldwide. Insulet is renowned for its innovative approach in the healthcare sector, particularly in the development and distribution of its flagship product, the Omnipod Insulin Management System. This system represents a significant advancement in diabetes care, offering a tubeless, wearable insulin pump that has transformed the way people with diabetes manage their condition. By focusing on user-friendly technology and accessibility, Insulet aims to improve the quality of life for individuals with diabetes, making it easier for them to control their health with more freedom and flexibility.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

For the full year 2024, Insulet achieved revenue of $2.1 billion, a 22.1% increase compared to $1.7 billion in the prior year, surpassing the guidance range of 20% to 21% growth in constant currency. The fourth quarter revenue reached $597.5 million, up 17.2% from the previous year, also exceeding the expected growth range.

Profitability

Net income for the full year was $418.3 million, more than doubling from $206.3 million in 2023. The fourth quarter reported a net income of $100.7 million, maintaining strong profitability despite slight year-over-year decreases. Gross margins improved to 69.8% for the year and 72.1% for the quarter, reflecting effective cost management.

Cash Flow

Operating cash flow significantly increased to $430.3 million for the full year, up from $145.7 million the previous year. Free cash flow also rose to $305.4 million, compared to $70.1 million in 2023, highlighting the company’s strong cash generation capabilities.

Product and Market Expansion

Insulet continued to expand its Omnipod product line, with Omnipod 5 now available to both type 1 and type 2 diabetes patients in the U.S. The company also launched Omnipod 5 in several international markets, contributing to a 27.6% increase in international revenue. Achieving 500,000 active global customers underscores the growing adoption of its innovative insulin management systems.

Future Outlook

Insulet provided a positive outlook for 2025, expecting revenue growth between 16% to 20% for the full year and 22% to 25% for the first quarter. The company anticipates continued expansion in both U.S. and international markets, supported by strong product demand and strategic initiatives.

Summarized from source with an LLMView Source

Key figures

26.4%1Y

14.0%3Y

24.9%5Y

Performance

37.0%1Y

37.9%3Y

42.1%5Y

Volatility